Convalescent Plasma Therapy on Critically-ill Novel Coronavirus (COVID-19) Patients
NCT04441424
·
clinicaltrials.gov ↗
NA
Phase
COMPLETED
Status
49
Enrollment
OTHER_GOV
Sponsor class
Conditions
IMMUNOTHERAPY
Interventions
BIOLOGICAL:
Convalescent plasma
DRUG:
Hydroxychloroquin with Azithromycin
Sponsor
Alkarkh Health Directorate-Baghdad